Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:28:13 EDT Wed 08 Jul 2026
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.92.92·3.001.23.0211.2327    3.21  0.9108:01:24Jul 0615 min RT 2¢

Recent Trades - All 7 today
Time ETExPriceChangeVolume
08:01:24Q2.97-0.054
07:16:47Q2.9063-0.1137123
07:06:59Q2.90-0.122,000
07:06:59Q2.90-0.121,200
07:06:55Q2.90-0.121
07:06:55Q2.90-0.12290
07:06:42Q2.90-0.121,900
07:00:02Q2.987-0.0332
05:22:05Q2.90-0.121
04:59:24Q2.90-0.1210

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-06 08:30U:FATENews ReleaseFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
2026-07-01 16:05U:FATENews ReleaseFate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
2026-06-15 08:30U:FATENews ReleaseFate Therapeutics Appoints Laura Hamill to Board of Directors
2026-06-12 08:10U:FATENews ReleaseAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
2026-06-08 09:01U:FATENews ReleaseThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
2026-06-04 08:30U:FATENews ReleaseFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
2026-06-02 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 08:30U:FATENews ReleaseFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
2026-05-21 08:30U:FATENews ReleaseFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-13 08:30U:FATENews ReleaseFate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
2026-05-11 08:30U:FATENews ReleaseFate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
2026-05-05 08:30U:FATENews ReleaseFate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
2026-05-04 09:00U:FATENews ReleaseFate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
2026-05-01 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-04-30 09:00U:FATENews ReleaseFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting
2026-04-16 09:00U:FATENews ReleaseFate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu
2026-04-09 09:00U:FATENews ReleaseFate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
2026-04-02 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-03-27 09:15U:FATENews ReleaseScalable Biotech Manufacturing Unlocks a $14B Market